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Abstract
Background: Gallbladder cancer is the most common billiary tract malignancy and carries a very
poor prognosis. Somatostatin was recently shown to play an important role in the development of
various tumors. In the current study, we evaluated the effect of doxorubicin on the
chemosensitivity of gallbladder cancer cells and xenograft growth after treatment with
somatostatin.
Methods: Twenty-four hours after somatostatin treatment, doxorubicin was gradually added and
the growth curve of gallbladder cancer cells was determined. Exponential-phase gallbladder cancer
cells were treated with doxorubicine or co-treated with doxorubicine and somastatine and the
respective IC50 values were determined. In addition, the inhibitory effect on the growth of
gallbladder cancer xenograft on nude mice was evaluated using the same treatments as those
described above.
Results: Treatment of gallbladder cancer cells with somatostatin led to a block in the cell cycle at
the S phase. Growth inhibition of gallbladder cancer cells by doxorubicin was concentration-
dependent (P < 0.05). However, upon co-treatment with doxorubicin and somatostatin, the IC50
value significantly decreased as compared to that of cells treated with doxorubicine alone (P <
0.05). Interestingly, treatment with either doxorubicin or somatostatin did not significantly inhibit
xenograft growth on nude mice, in contrast to a co-treatment with both drugs (P < 0.05).
Conclusion: Somatostatin most likely sensitizes the chemotherapeutic effect and diminishes the
cytotoxicity of doxorubicin in a gallbladder cancer cell line and in mouse gallbladder cancer
xenografts.
Background
Gallbladder cancer is the most common billiary tract
malignancy and known as an aggressive and highly fatal
disease with still a poor prognosis. Although relatively
uncommon in Europe and the United States, gallbladder
carcinoma is often reported in countries such as South-
America, India, and Poland [1]. Symptoms often associ-
ated with gallbladder carcinoma include pain in the right
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hypochondrium, weight loss, anorexia, nausea and vom-
iting, and lump in the right hypochondrium [1]. In some
rare cases, patients exhibit a primary non-Hodgkin lym-
phoma of the gallbladder [2]. Although the correlation
between gallstones and gallbladder cancer is yet not well
understood, the presence of gallstones is generally consid-
ered as an important risk factor for gallbladder cancer.
Gallbladder carcinoma is most often reported in females
and the 5-year survival rate varies between 0 and 10%. A
recent long-term study reports that the survival rate of
patients with gallbladder cancer has slightly improved
over the past 85 years, but remains remarkably low [3].
This was also noticed in the P.R. China where the inci-
dence rate of gallbladder cancer increased during the past
decades whereas the survival rate remained unsatisfactory.
Despite recent research on therapeutic strategies against
gallbladder carcinoma, surgical resection still appears to
be the only potentially curative approach for this disease.
Unfortunately, only a minority of patients is eligible to
undergo surgery and, moreover, surgical removal of the
gallbladder tumor does not necessarily implicate that the
patient will recover in the long run [1]. Alternative thera-
pies, such as radio- and chemotherapy, which has a sub-
stantial effect on metastatic pancreatic neuroendocrine
tumors [4], for the treatment of gallbladder carcinoma
have met with various degrees of success as gallbladder
cancer cells are little sensitive to either of those
approaches [1,5]. In a recent report, a clinical study on 5
patients diagnosed with advanced gallbladder carcinoma
demonstrated that treatment with the pyrimidine antime-
tabolite gemcitabine might be a safe and effective treat-
ment for advanced or metastatic gallbladder carcinoma
[6]. The response of gemcitabine was enhanced in the
presence of cisplatin [1]. Reports on the use of radiother-
apy to treat gallbladder carcinoma are not encouraging
[1]. Nevertheless, because the recurrence pattern is distant
and local, it might be a helpful therapy to perform prior
to or in combination with subsequent surgical resection
as it appears to substantially enhance the chance for suc-
cessful surgical resection [7]. In any case, it is obvious that
future studies should focus on the development of suc-
cessful strategies to treat gallbladder carcinoma.
Recent evidence showed that mis-regulation of the cell
cycle may initiate tumor development [8]. Components
involved in the proper regulation and functioning of the
cell cycle are often altered in human cancer cells. A dereg-
ulation of crucial regulatory elements of the cell cycle may
lead to an unlimited and uncontrolled mitosis and
thereby provide selective cells with an advantaged growth
pattern leading to the formation of cancer cells and thus
the development of a tumor [9]. Consequently, several
anticancer agents under study exhibit an inhibitory effect
on the cancer cell's cell cycle.
Somatostatin (SST), a neuropeptide produced by neu-
roendocrine, inflammatory, and immune cells upon trig-
gering different responses, has been used as a regulator of
many hormones in clinical studies and plays an impor-
tant role in the development of various tumors [10]. In
the current study, the effect of SST on the regulation of
growth and cell cycle of gallbladder cancer cells was inves-
tigated. The modulation effect of SST on the chemosensi-
tivity of an anti-neoplastic drug, doxorubicin (DOX),
which is one of the most effective anthracycline antibiot-
ics with a broad antitumor spectrum [11], was evaluated
as well. The ability of SST to enhance the cytotoxic effect
of DOX on gallbladder cancer cells [12] was further elab-
orated as well as the effect of a DOX-SST co-treatment of
nude mice harboring a gallbladder cancer xenograft.
Methods
Cell line culture and establishment of xenografts in nude 
mice
The human gallbladder carcinoma cell line GBC-SD was
purchased from the Cell Bank of the Chinese Academic of
Sciences (Shanghai). Cells were grown at 37°C in a
humidified atmosphere containing 5% CO2  in RPMI
1640 medium (Gibco BRL, Carlsbad, CA) supplemented
with fetal bovine serum (10%; Gibco BRL), glutamine (2
mM), penicillin (100 IU/ml), and streptomycin (100 μg/
ml). Cells used in drug treatments or to inject mice were
grown until the exponential growth phase.
Exponential-phase cells were trypsinized, washed with
RPMI 1640, and suspended in saline solution to obtain a
concentration of 5 × 106 cells/0.1 ml. Subsequently, 0.1
ml cell suspension was injected into each nude mouse
(Experimental Animal Center, Chinese Academic of Sci-
ence, Shanghai), subcutaneous in the axilla bilaterally.
Formation of a tumor with a diameter of 5 mm was
observed approximately 1 week after cell inoculation.
Cell cycle analysis
GBC-SD cells were plated in six-well plates (Corning, New
York, NY). Cells floating in the medium were combined
with the adherent cell layer, which was then trypsinized.
Cells were treated with SST (75 μg/ml; Serono Co., Swit-
zerland) for 12, 24, 72, and 120 h and subsequently, 5 ×
105 cells were washed, pelleted, and then incubated with
2 mg/ml RNase A in phosphate-buffered saline (PBS, 200
μl) and 0.1 mg/ml propidium iodide in 0.6% nonidet P-
40 in PBS (200 μl) on ice for 30 min. Samples were imme-
diately analyzed by flow cytometry using a fluorescence
acquired cell sorter (FACS Calibur, Becton Dickinson Co.,
Franklin Lakes, NJ). The DNA content histograms were
analyzed to determine the cell cycle phase distribution of
the gallbladder cancer cells using the CELLQUEST soft-
ware (Becton Dickinson).BMC Cancer 2007, 7:125 http://www.biomedcentral.com/1471-2407/7/125
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Cell viability assay
Cells from monolayer-grown GBC-SD cultures were har-
vested and dispensed in 96-well culture plates in 200 μl
medium at a concentration of 105 cells per well. Cells were
divided into three groups: DOX-use-only group, co-use-
group (co-treatment with DOX (Sigma Chemicals, St.-
Louis, MO) and SST), and control group. In the control
group, PBS was added to the cells. DOX was applied in the
following gradient concentrations: 0, 3.33, 6.66, 13.32,
19.98, and 33.30 μg/ml and the intracellular uptake was
determined [11]. In the co-use group, cells were first
treated with 75 μg/ml SST for 24 h followed by the addi-
tion of DOX in the gradient concentrations mentioned
above. The cell viability was measured after 48 h of incu-
bation using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) colorimetric assay
[13,14]. Ten microliter MTT (5 mg/ml in PBS) was added
to each well. After 4 h incubation at 37°C, supernatants
were removed and replaced by 150 μl dimethyl sulfoxide.
After formazan solubilization, the optical density at 590
nm (OD590) of each well was measured using an auto-
mated microplate reader (Bio-Rad Model 550, Microplate
Reader, Hercules, CA). The cell viability was calculated
using the following equation: cell viability = mean OD of
one group/mean of the control × 100%
Xenograft growth inhibition assay
Twenty-five nude mice bearing a xenograft were randomly
divided into five groups: DOX-use-only group (2 mg/kg
DOX), SST-use-only group (1 mg/kg SST), co-use group 1
(2 mg/kg DOX plus 1 mg/kg SST), co-use group 2 (2 mg/
kg DOX plus 2 mg/kg SST), and the control group. The use
and care of animals follwed the guidelines of the Ethical
Committee of Xinhua Hospital, School of Medicine,
Shanghai Jiaotong University. SST was injected daily,
intraperitoneal, from the first day until the ninth day and
DOX was injected every other day, intraperitoneal, from
the second day until the eighth day (4 times). Those injec-
tions were combined in case of the co-use-group. Twenty-
four days after the injection of mice with gallbladder can-
cer cells, tumors were harvested and the wet weight was
determined.
Statistical analyses
Because of the limited number of samples, the Wilcoxson
rank sum test, a non-parametric method that allows to test
independent samples, was applied to determine whether
a given mean was significantly different from a respective
control (P < 0.05). The SPSS software for Windows (ver-
sion 13.0) was utilized to perform all the statistical analy-
ses and the significance level (αvalue) was set at 0.05.
Results
Treatment of gallbladder cancer cells with SST causes cell 
cycle arrest
Because of the reported possible interactions between cell
cycle deregulation and tumor development [9], we inves-
tigated the effect of SST on the cell cycle using the gall-
bladder cancer cell line GBC-SD grown to the exponential
growth phase. This cell line exhibited a doubling time in
the range of 25 to 30 h (date not shown). SST was applied
in a concentration of 75 μg/ml and the ratio of cells in the
S phase was determined after 12, 24, 72, and 120 h incu-
bation.
The ratio of cells in the S phase increased 12 h after treat-
ment with SST and was significantly higher than that for
the control group 24 h after SST treatment (Figure 1A).
However, the ratio of cells in the S phase rapidly decreased
72 h after SST treatment and was similar to that in the con-
trol group after 120 h incubation in the presence of SST
(Figure 1A).
Simultaneously, for each time point at which the ratio of
cells in the S phase was determined (Figure 1A), we meas-
ured the apoptosis index, indicative for the number of
cells that underwent cell death. We observed that after 12
h SST treatment, the apoptosis index significantly
increased as compared to that for the control group and
kept increasing in time (Figure 1B).
DOX and SST exhibit a synergistic inhibitory effect on the 
growth of gallbladder cancer cells
In first instance, we determined the effect of DOX on cell
growth using the GBC-SD cell line grown to the exponen-
tial growth phase. The concentration of DOX was gradu-
ally increased from 0 to 33.30 μg/ml (Methods) and the
cell viability was measured in time. The cell growth was
significantly inhibited at higher DOX concentrations (Fig-
ure 2). The DOX-mediated inhibition of gallbladder can-
cer cell growth was concentration-dependent (Figure 2).
Furthermore, we determined the effect of co-treatment
with DOX and SST on the growth of GBC-SD cells (Figure
2). Cell growth inhibition occurred more rapidly in time
as compared to that of cells treated with only DOX (Figure
2). The hastened cell growth inhibition was significant
and confirmed by the calculation of the IC50 values which
were 15.00 μg/ml DOX upon treatment of the gallbladder
cancer cell line with only DOX and 4.50 μg/ml upon co-
treatment with DOX and SST (Figure 2; P < 0.01).
Inhibition of xenograft growth by co-treatment with DOX 
and SST
To investigate the effect of co-treatment with DOX and
SST on the tumor growth in a mouse model system, we
injected nude mice with gallbladder cancer cells grown toBMC Cancer 2007, 7:125 http://www.biomedcentral.com/1471-2407/7/125
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the exponential growth phase. Mice were either not
treated, treated with DOX or SST, or co-treated with DOX
and SST using two different concentrations of SST.
Twenty-four days after the injection of mice with gallblad-
der cancer cells, the tumors were harvested and their wet
weight was measured.
We observed that treatment with either DOX or SST alone
did not significantly inhibit tumor growth in contrast to
co-treatment with DOX and the lower concentration (1
mg/kg) of SST (Figure 3). The latter growth inhibition,
indicated by a lower wet weight of the tumors, was signif-
icant (P < 0.05). Because the number of mice tested in this
experiment was relatively low, we evaluated and calcu-
lated the statistical power. Using the nQuery Advisor® soft-
ware to perform the Wilcoxson rank sum test, we
determined the power for the two significant tests in Fig-
ure 3, examining the difference in the average tumor
weight between mice co-treated with 2 mg/kg DOX and 1
mg/kg SST and control mice, and mice co-treated with 2
mg/kg DOX and 2 mg/kg SST and control mice. The
power was 0.51 and 0.64, respectively.
Discussion
Gallbladder carcinoma is a devastating disease for which
the only feasible cure, at least for some patients, is surgical
resection. Unfortunately, surgical resection only helps
some gallbladder cancer patients and the long-term sur-
vival rate remains low [1]. It is remarkable that to date no
successful alternative therapies have been developed,
mainly because gallbladder cancer cells are relatively little
sensitive to commonly used therapies such as radiother-
Inhibition of GBC-SD cell growth in the presence of DOX  (solid line) or DOX and SST (dashed line) Figure 2
Inhibition of GBC-SD cell growth in the presence of DOX 
(solid line) or DOX and SST (dashed line). The relative sur-
vival percentage is shown. Means that are significantly differ-
ent from the control group are indicated with an asterisk (P 
< 0.05).
S-phase cell ratio (A) and apoptosis index (B) of gallbladder  cancer cells (cell line GBC-SD) treated with SST (75 μg/ml)  for 12, 24, 72, and 120 h Figure 1
S-phase cell ratio (A) and apoptosis index (B) of gallbladder 
cancer cells (cell line GBC-SD) treated with SST (75 μg/ml) 
for 12, 24, 72, and 120 h. Means that are significantly different 
from the control group are indicated with an asterisk (P < 
0.05).BMC Cancer 2007, 7:125 http://www.biomedcentral.com/1471-2407/7/125
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apy and chemotherapy. Therefore, it is crucial to engineer
and design new strategies that may ultimately lead to the
discovery of an effective and safe, non-surgical treatment
of gallbladder carcinoma.
More evidence is becoming available that demonstrates
the interconnection between cell cycle deregulation and
tumor development [9]. It has been demonstrated that a
positive correlation exists between the status of p53, a
tumor suppressor protein that in response to cellular stim-
uli controls the expression of genes involved in the con-
trol of cell cycle arrest and cell death [15], and the
chemosensitivity of, for instance, ovarian cancer cells
[16,17]. In fact, environmental factors that cause DNA
damage lead to the phosphorylation of p53 which pre-
vents a pathway required for the transcription of S-phase
genes, thereby maintaining G1/S phase arrest [18]. Inter-
estingly, SST induced p53 production in human breast
cancer cells, exhibiting p53 depletion, which resulted in
cell growth arrest [19]. It has been postulated that SST
directly stimulates tumor cell apoptosis via SST receptor 3-
dependent G-protein signaling which causes, among
other factors, the induction of p53 suppressor gene
expression [20]. Here, we demonstrate using flow cytom-
etry that the ratio of gallbladder cancer cells in the S phase
increases upon treatment with SST for 24 h. While this
remains to be proven, those observations strongly suggest
that gallbladder cancer cells treated with SST are arrested
at G1/S transition, a process which is likely mediated by
p53.
SST has been used as a regulator of secretion of many gas-
trointestinal hormones in the clinic for a long time. In
addition, SST and its stable analogues were shown to exert
an anti-proliferative effect on various cancerous cells both
in vitro and in vivo [10]. This is confirmed by our results
as we demonstrated that SST significantly inhibits cell
growth in a gallbladder cancer cell line in a concentration-
dependent manner [21]. Thus, SST likely inhibits gall-
bladder cancer cell growth by arresting the cell cycle at the
S phase and inducing apoptosis which is the subject of
further studies. The latter observations illustrate that gall-
bladder cancer cells appear to be relatively sensitive to
treatment with SST which may have important clinical
applications.
However, the effect of SST on the growth of gallbladder
cancer cells was observed at fairly high SST concentration
(i.e., 75 μg/ml) which is tenfold higher than the SST con-
centration generally used in other applications. This high
concentration would prohibit its use in human patients as
it might have severe cytostatic and cytotoxic effects [9]. In
addition, we noticed that such a high SST concentration
did not affect the growth of gallbladder cancer xenografts
on nude mice. Therefore, we investigated the hypothesis
whether co-treatment with a chemotherapeutic drug that
functions by interrupting DNA synthesis in the S phase of
the cell cycle would enhance the inhibitory effect of SST
on gallbladder cancer cell growth and thus lowers the
workable SST concentration.
DOX is an anthracycline antibiotic often used as a classic
chemotherapeutic drug which exhibits an antitumor effect
caused by intercalation into DNA molecules [11]. Unfor-
tunately, gallbladder cancer cells appear to be rather resist-
ant to treatment with DOX and many other
chemotherapeutic agents. Although gallbladder cancer
cell growth inhibition by DOX was observed and concen-
tration-dependent [22], the DOX concentration needed to
induce antitumor effects was fairly high. Strikingly, a co-
treatment of gallbladder cancer cells with SST and DOX
reduced the IC50 value from 15 μg/ml DOX in the pres-
ence of DOX alone to 4.5 μg/ml in the presence of both
DOX and SST. This co-treatment, in contrast to treatments
with either DOX or SST, also significantly reduced the wet
weight of gallbladder cancer xenografts developed on
nude mice.
Taken together, these data strongly suggest that modula-
tion of the cell cycle by treatment of SST could sensitize
chemotherapy, both in a gallbladder cancer cell line and
gallbladder cancer xenografts developed on nude mice.
Although the underlying molecular mechanisms that
could explain this synergistic inhibitory effect on gallblad-
der cancer cell growth remain to be elucidated, it is possi-
ble that treatment with SST reduces the expression of high
Inhibition of gallbladder cancer xenograft growth on nude  mice upon treatment with SST (1 mg/kg), DOX (2 mg/kg), or  a combination of both (2 mg/kg DOX with either 1 mg/kg or  2 mg/kg SST) Figure 3
Inhibition of gallbladder cancer xenograft growth on nude 
mice upon treatment with SST (1 mg/kg), DOX (2 mg/kg), or 
a combination of both (2 mg/kg DOX with either 1 mg/kg or 
2 mg/kg SST). Means that are significantly different from the 
control group are indicated with an asterisk (P < 0.05).BMC Cancer 2007, 7:125 http://www.biomedcentral.com/1471-2407/7/125
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affinity SST receptors in gallbladder cancer cells, an effect
of SST that has been demonstrated in pancreatic tumor
cell lines [23], which may alter the landscape of receptors
and other cell surface proteins on gallbladder cancer cells.
The latter may substantially increase the sensitivity of
those cancer cells to DNA synthesis-disrupting chemo-
therapeutic agents. Future work is required to further eval-
uate this hypothesis.
Although the way to a successful non-surgical therapy for
gallbladder carcinoma is still long, the results presented
herein provide new insights in a possible chemotherapeu-
tic approach in combination with an SST treatment which
would allow gallbladder cancer cells to arrest their cell
cycle. Future studies are required to unravel the underly-
ing molecular pathways that explain the synergistic inhib-
itory effect of the DOX-SST co-treatment on gallbladder
carcinoma development and to pinpoint the selectivity of
those drugs in human patients diagnosed with advanced
gallbladder carcinoma.
Conclusion
Pre-treatment of a gallbladder carcinoma cell line with
somatostatin increased sensitivity to doxorubicin, as evi-
denced by inhibition of cancer cell growth both in vitro
and in vivo.
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